An update on the epidemiology of aspirin-exacerbated respiratory disease.

Related Articles

An update on the epidemiology of aspirin-exacerbated respiratory disease.

Am J Rhinol Allergy. 2017 Sep 01;31(5):299-301

Authors: White AA

Abstract
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is a disorder of nasal polyposis, asthma, and hypersensitivity respiratory reactions when on systemic cyclooxygenase 1 blockade.
METHODS: AERD warrants specific evaluation as an endotype of asthma and chronic sinus disease due to unique therapeutic opportunities. Currently, aspirin therapy is uniquely beneficial as an anti-inflammatory therapy in AERD, with multiple additional therapies currently in early to late clinical studies, which might also show exceptional benefit in AERD.
RESULTS: Yet, given the lack of a simple diagnostic test, opportunities to identify patients with AERD are still frequently neglected.
CONCLUSION: Identifying the prevalence and population characteristics necessary to determine appropriate candidates in whom to perform diagnostic aspirin challenge remains critically important and was the purpose of this article.

PMID: 28859704 [PubMed - in process]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/2x13ivQ